volume 229, issue 4, P333-344 1980
DOI: 10.1007/bf02108584
View full text
Sign up to set email alerts

Abstract: Proteohormone receptors have been demonstrated in gynecological malignancies, but more sensitive methods for measurement of such receptors are required and should be a matter of intensive research. The clinical response of hormone-dependent tumors to endocrine therapy has not yet been correlated with the occurrence of proteo-hormone receptors in neoplastic tissue from gynecological patients and such studies are required.